Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour.
A 62-year-old woman with a pre-existing psoriasis was treated with oral imatinib (400 mg/day) for a metastatic gastrointestinal stromal tumour. Within 4 weeks of starting therapy, she developed a guttate psoriasis flare. The eruption markedly improved within 2 weeks following cessation of imatinib. However, it recurred when imatinib was recommenced. She has been able to continue on imatinib (400 mg/day) with low-dose oral methotrexate (12.5 mg/week) controlling the psoriasis.
Cheng
Haiying
H
Department of Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts 01655-0002, USA. chengh@ummhc.org
Geist
David E
DE
Piperdi
May
M
Virk
Renu
R
Piperdi
Bilal
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D008727:Methotrexate